The X protein (HBX) of the hepatitis B virus (HBV) is not essential for the HBV life cycle in vitro but is important for productive infection in vivo. Our previous study suggests that interaction of HBX with the proteasome complex may underlie the pleiotropic functions of HBX. With the woodchuck model, we demonstrated that the X-deficient mutants of woodchuck hepatitis virus (WHV) are not completely replication defective, possibly behaving like attenuated viruses. In the present study, we analyzed the effects of the proteasome inhibitors on the replication of wild-type and X-negative HBV and WHV. Recombinant adenoviruses or baculoviruses expressing replicating HBV or WHV genomes have been developed as a robust and convenient system to study viral replication in tissue culture. In cells infected with either the recombinant adenovirus-HBV or baculovirus-WHV, the replication level of the X-negative construct was about 10% of that of the wild-type virus. In the presence of proteasome inhibitors, the replication of the wild-type virus was not affected, while the replication of the X-negative virus of either HBV or WHV was enhanced and restored to the wild-type level. Our data suggest that HBX affects hepadnavirus replication through a proteasome-dependent pathway.
Human hepatitis B virus (HBV) is a member of the Hepadnaviridae family, which includes the hepatitis viruses of the woodchuck, ground squirrel, tree squirrel, Pekin duck, and heron. HBV has a fourth open reading frame, termed the hepatitis B virus X (HBX) gene. The HBX gene is well conserved among the mammalian hepadnaviruses and codes for a 16.5-kDa protein. The protein can activate the transcription of a variety of viral and cellular genes (1, 7) . Since HBX does not bind to DNA directly, its activity is thought to be mediated via protein-protein interaction. HBX has been shown to enhance transcription through AP-1 and AP-2 (2, 24) and to activate various signal transduction pathways (9, 11) . Several recent studies have also identified possible cellular targets of HBX, including members of the CREB/ATF family (19) , the TATAbinding protein (20) , RNA polymerase subunit RPB5 (6), the UV-damaged DNA-binding protein (25) , the replicative senescence p55 sen (28) , and the mitochondrial protein (31) . HBX has also been shown to interact with p53 and inhibit its function (29, 30) . Furthermore, X protein is necessary for the establishment of a productive infection in vivo (5, 37) . Recent results have demonstrated that signaling through calcium may mediate a function of HBX in viral replication, and calcium chelator can inhibit viral replication by blocking the effect of HBX (4) .
We have previously demonstrated that the proteasome complex is a cellular target of HBX (18, 34) . We demonstrated that this interaction is functionally important in the pleiotropic effect of HBX (17) . With the woodchuck model, we demonstrated that the X-deficient mutants of woodchuck hepatitis virus (WHV) are not completely replication defective, behaving like attenuated viruses (35) .
Adenovirus and baculovirus vectors have been used for efficient transduction of foreign genes, especially in hepatocytederived cell lines. Recombinant adenovirus or baculovirus expressing hepadnavirus genome has recently been shown to be a robust and convenient system for studying HBV replication in tissue culture (10, 27) . Such a system is superior to transfection of viral genomic DNA because it is more efficient and supports the full cycle of viral replication, including the production of covalently closed-circle DNA (cccDNA) (10, 27) . In the present study, we constructed recombinant adenoviruses or baculoviruses expressing replicating HBV or WHV genomes with or without a functional X gene. Using these recombinant viruses, we determined the effects of proteasome inhibitors on the functions of the X protein in hepadnavirus replication and proved that proteasome inhibitors restored the replication defect of X-negative HBV and WHV.
MATERIALS AND METHODS
Plasmid construction. Recombinant adenovirus expressing the HBV genome was generated using the AdEasy system (16) . A 1.3ϫ genome of HBV DNA was cloned into an adenovirus vector to generate the adHBV recombinant virus, as previously described (27) . For the construction of the HBV X mutant, a C-to-T mutation was introduced to create a premature stop codon of the X open reading frame at amino acid position 8 of the 5Ј and 3Ј terminal redundant region of the 1.3ϫ genome (adHBVXϪ) (see Fig. 1A ). To generate recombinant baculovirus expressing the WHV genome, the polyhedrin promoter of the baculovirus vector pFastBac (Bac-to-Bac; Gibco-BRL, Gaithersburg, Md.) was deleted, and a 1.2ϫ full-length genome of an infectious WHV strain (13) driven by the cytomegalovirus promoter was cloned into the EcoRI sites of the promoterless pFastBac vector, resulting in the baculovirus-WHV wild type, bvWHV. The bvWHV X mutant was created by introducing an ATG-to-TTG mutation at the first translation initiation site of WHVX of bvWHV, resulting in bvWHVXϪ (see Fig. 1B ).
Cell cultures. Sf9 insect cells were maintained in a flask at 28°C in Sf-900 II serum-free medium (Gibco-BRL). Recombinant baculoviruses were generated and amplified in Sf9 cells. The 293 cells were maintained in Dulbecco's modified Eagle's medium (Gibco-BRL) containing 10% fetal bovine serum in a humidified incubator (5% CO 2 ) and used for generation and amplification of adenoviruses as described previously (27) . The human hepatoma HepG2 or Huh7 cells were grown in Dulbecco's modified Eagle's medium (Gibco-BRL) containing 10% fetal bovine serum in a humidified incubator (5% CO 2 ).
Proteasome inhibitors and calcium signaling reagents. Proteasome-specific inhibitors lactacystin (Kamiya Biomedical Company, Seattle, Wash.), MG132 (Proscript, Inc., Cambridge, Mass.), and epoxomicin (Peptides Institute Inc., Osaka, Japan) and N-acetyl-L-leucinyl-L-methonal (ALLM; Sigma Chemical Co., St. Louis, Mo.), a potent calpain inhibitor that has only a very weak activity against the proteasome, were used. Calcium signaling reagents BAPTA-AM (cytosolic calcium chelator) and valinomycin (calcium mobilizing agent) were obtained from BIOMOL Research Laboratories Inc. (Plymouth Meeting, Pa.). Viral nucleic acid analysis. HepG2 cells were infected with recombinant adenovirus-HBV or baculovirus-WHV as described above. Three days after infection, the cells were harvested for viral RNA and DNA analyses. RNA was prepared by the guanidium isothiocyanate-acid-phenol method (TRIzol RNA isolation Kit; Invitrogen, Carlsbad, Calif.), analyzed by 1% formaldehyde agarose gel electrophoresis, and hybridized with 32 P-labeled WHV-or HBV-specific probe. Viral replicative intermediates associated with intracellular core particles were isolated by ultracentrifugation of cell lysate through a 30% sucrose cushion and analyzed by Southern blot hybridization as described previously (15) . Viral antigen assays. After bvWHV or adHBV infection, culture medium was analyzed for WHV surface antigen using solid-phase radioimmunoassay (35) or HBV surface antigen using AUSZYME (ABBOTT Laboratories, Abbott Park, Ill.) and for HBV e antigen using ETI-EBK PPLUS (DiaSorin Inc., Stillwater, Minn.).
Infection of

RESULTS
Effect of X on viral replication in cells infected with recombinant viruses.
To study the effect of HBX on HBV replication, we generated an adenovirus (adHBV) expressing HBV and a recombinant baculovirus (bvWHV) expressing the WHV genome ( Fig. 1 ) in HepG2 cells. HepG2 cells were infected with the recombinant viruses at MOIs ranging from 0.1 to 50 for adHBV or 10 to 100 for bvWHV. To evaluate viral replication, cytoplasmic core particles were prepared 3 days postinfection and the core-associated viral DNA was extracted for the analysis of replicative intermediates. Figure 2A shows HBV replication and Fig. 2B shows WHV replication in HepG2 cells. The X mutants replicated at about 10% of the wild-type HBV or WHV level, which is consistent with previous results (3, 35) . Both wild-type and X mutants replicated at levels proportional to the MOI. Therefore, adHBV or bvWHV infection offers an efficient and dose-dependent replication of hepadnavirus genomes in the human hepatoma HepG2 cells.
Effect of proteasome inhibitors on hepadnavirus replication. To test whether the proteasome pathway is involved in HBV replication, HepG2 cells were infected with adHBV or bvWHV, described above, and then treated with different doses of proteasome-specific inhibitors. The cells were also treated with ALLM, a calpain inhibitor with little effect on the proteasome activity, as a nonspecific control. After treatment, the cells were harvested and analyzed for viral gene expression and replication. In cells infected with recombinant viruses, the replication level of the X-negative virus was about 10% of that of the wild type. However, in the presence of proteasome inhibitors, the replication of the wild type was not affected, whereas the replication of the X-negative virus, either HBV (Fig. 3A) or WHV (Fig. 4A) , was restored to the wild-type level. Treatment with ALLM had no effect on replication of either the wild type or the X-negative mutant for either HBV (Fig. 3A) or WHV (data not shown). To test whether the proteasome inhibitors have any effects on viral gene expression at the level of transcription and protein synthesis, total RNA from the infected cells was isolated and analyzed by Northern blotting, and the culture medium of the infected cells was assayed for viral antigens. There was little difference in viral transcription with or without proteasome inhibitors in cells . No significant differences were detected in viral antigen production ( Fig. 3C and D for HBV and 4C for WHV). In the HBV and WHV experiments, presumably toxic effects of proteasome inhibitors were seen at the high concentration, contributing to the lower levels of replication, transcription, and/or protein production (Fig. 4) . The proteasome inhibitors appeared to affect viral replication of only X-negative virus but not wild-type virus, suggesting that the proteasome pathway plays an important role in the function of HBX in viral replication. The HBV X gene is known to affect HBV replication in HepG2 cells but not Huh7 cells. We therefore infected Huh7 cells with AdHBV wild-type or X-negative viruses and examined the effect of proteasome inhibitors on HBV replication. No significant differences were detected in the levels of viral replication between wild-type and X-negative viruses (Fig. 5) . Treatment with proteasome inhibitors (LC, EPOX, and MG132) or the calpin inhibitor ALLM had no effect on HBV replication of either wild-type or X-negative viruses (Fig. 5) . Therefore, the proteasome inhibitors affect replication of Xnegative HBV only in cells in which the X gene is functional.
Effect of calcium signaling on function of HBX in HBV replication. To examine whether the function of HBX in HBV replication is mediated by the calcium signaling pathway, as suggested by a recent publication (4), we tested the effects of various calcium signaling reagents on HBV replication using the recombinant virus systems. HepG2 cells were infected with adHBV or bvWHV and then treated with two calcium signaling reagents, BAPTA-AM (which chelates cytosolic calcium and inhibits calcium signaling) and valinomycin (which mobilizes intracellular calcium to activate the calcium signaling pathway). After 3 days of treatment, cytoplasmic viral core particles were isolated and the core-associated viral DNA was extracted for the analysis of replicative intermediates (Fig. 6) . Treatment with either of the reagents appeared to have little effect on viral replication of either wild-type or X-negative viruses.
DISCUSSION
The molecular mechanisms by which HBX attains its biological functions in HBV replication remain largely unresolved, despite compelling evidence that HBX is crucial for productive infection in vivo. Numerous studies have provided tantalizing evidence about the potential cellular targets and functions of HBX, but most of them have not been thoroughly tested in a relevant biological system nor rigorously examined with respect to viral replication. We have previously demonstrated the structural and functional interaction between HBX and the proteasome complex (17, 18, 34) and that the molecularly constructed HBX mutants deficient in interaction with proteasome in vitro behave as attenuated viruses in vivo (35) . In this study we further demonstrated the biological importance of the proteasome complex in the functional pathway of HBX in the context of HBV replication. Using specific proteasome inhibitors and two model systems that have been shown to be robust and reproducible in studying the complete replication cycle of HBV, including the generation of cccDNA, we showed that the reduced viral replication of the HBX-defective mutant can be restored in the presence of various proteasome-specific inhibitors. On the other hand, these inhibitors appear to have little effect on wild-type replication. This phenomenon is specific for the proteasome activities, because other protease inhibitors had no effect. HBV and WHV appear to behave the same way in response to the proteasome inhibitors. The doses of the proteasome inhibitors used in the study are low and have a minor or no toxic effect on the cells for the duration of treatment (with the exception of the higher dose of MG132). In addition, the specific effect of the proteasome inhibitors on X-negative but not wild-type viruses supports the notion that this observation is biologically relevant. The proteasome inhibitors had little effect on viral transcription and protein production. Therefore, the enhanced replication of the HBX mutant in the presence of the inhibitors appears to be operational at the posttranslational and most likely the assembly level. This is consistent with the functional effect of HBX on viral replication and the potential interaction point of the proteasome complex and HBX. HBX possibly inhibits the degradation of nucleocapsid by proteasome during the assembly process, as a mechanism of promoting viral replication and inhibiting the cellular antiviral pathway (26) . In light of recent studies showing the importance of proteasome in the endogenous antiviral response to viral infection (22, 23) , further experimentation is needed to prove our proposed mechanism of action by HBX.
Interestingly, interferons have been shown to be potent inhibitors of HBV replication either in vitro or in vivo (21, 32) . One of the well-known interferon-activated targets is the proteasome complex, which, in addition to other changes, acquires enhanced proteolytic activities after treatment with interferons (8, 12) . A recent study with HBV transgenic mice also pointed to a potentially critical role of proteasome activation in inhibiting HBV replication (32) . All these intriguing observations provide additional support that HBX-mediated interaction with the proteasome may underlie an important aspect of HBV replication.
The doses of proteasome inhibitors used in this study are below the effective concentrations that are required to fully inhibit the proteasome activities in tissue culture, but they are within the inhibitory concentrations in standard in vitro proteasome assays using purified proteasome complexes (8, 17) . It is possible that the multicatalytic functions of proteasome may be differentially sensitive to various inhibitors under diverse biological conditions. The lower dose with suboptimal inhibition of proteasome activities may be sufficient to effect the necessary changes for efficient viral replication in our model system. We could not use the fully effective doses because of the potential toxicity. Furthermore, in our previous publication, we were able to see effects of these concentrations of proteasome inhibitors on the HBX functions (17) . There are newer generations of proteasome inhibitors that are less toxic and have been used in vivo with success (36) . Perhaps these inhibitors can be used to study the function of HBX in the context of hepadnavirus replication in vivo.
A recent study demonstrated that HBX mediates its effect on HBV replication through activation of the calcium signaling pathway (4) . Using the viral delivery systems, we also tested the effects of two compounds, one inhibiting intracellular calcium mobilization and the other functioning as a calcium ionophore to activate the calcium signal pathway, on viral replication. In this recent publication, the former compound, BAPTA-AM, inhibits wild-type HBV replication, and the latter compound, valinomycin, enhances replication of an HBX-negative mutant. However, BAPTA-AM was not tested on HBX mutant replication, nor was valinomycin tested on wild-type replication (4). Interesting, we saw little or no effect of these two compounds on replication of either the wild-type or HBX-negative viruses. The explanation of the contrasting results of the two studies is not clear, but it is possible that the difference could be due to the different experimental systems used in each study. In the study by Bouchard et al. (4) , transfection of recircularized HBV genome was used, whereas we used the viral delivery system (either adenovirus or baculovirus) to transduce the viral genome. It is possible that the viral systems cause some untoward effects on HBV replication, so the functions of these compounds affecting the calcium signaling pathway are being masked with respect to viral replication. However, the viral delivery systems provide a more biological relevant model because of the generation of cccDNA, which is absent in the DNA transfection system. In addition, the observation that the proteasome inhibitors elicit a specific effect on the HBX-negative mutant but not the wild-type virus supports a physiological role of the proteasome in HBX-dependent HBV replication.
The ultimate proof of any pathways in the functions of HBX would have to be determined with an infectious and/or in vivo model. The recent description of a human hepatoma-derived cell line capable of supporting robust HBV infection and replication would be a valuable model with which to test these hypotheses (14) . In addition, the availability of several HBV transgenic mouse lines capable of supporting either wild-type or HBX mutant replication (33) provides a rational approach for testing the pharmacologic effects of various compounds targeting these pathways.
